Our study thus demonstrates that it may be possible to use PhadiatopTM as biomarker to determine cut-off levels of allergen-specific IgE above which clinical effects of IgE-targeted molecular therapy are better than in severe asthma patients with allergen-specific IgE levels below the cut-off. Here, IGHE is linked to asthma.